₹85,000 Temple: Deepinder Goyal’s wearable is a health-tech gamble

Temple, a new head-worn wellness wearable created by Zomato and Eternal founder Deepinder Goyal, is making news - primarily for its price point. Priced at ₹85,000, Goyal himself has pointed out that it is 'not made for India' but for a global consumer, adding, 'We don't expect any more than 1% of Temples being sold in India.' This flips the old Tata Motors '₹1 lakh Nano car for everyone' model on its head.

But what we're looking at is a rare phenomenon in Indian retail: the pioneer product. The emerging role of AI in healthcare resides in predictive diagnostics. Companies like Molbio Diagnostics are mobilising their machines in remote locations for primary screening, to be escalated to structured healthcare, upon due suspicion. Apps like Ada, Apple Health, mySugr and Qure.ai are effectively doing the same on a one-on-one interactive basis. Never as an alternative to the registered medical practitioner, but as a productive channel for timely and accurate intervention.

Also Read | Deepinder Goyal's Rs 85,000 Temple wearable faces scientific credibility test as doctors question claims


'Entropy', the stated tech driving Temple, is designed to be a real-time biomarker, assessing performance of the body during both rest and peak performance. Tracking how hard the body is working across multiple systems, on a scale of 1 to 250. In tandem with 'BrainFlow', designed to monitor relative changes in blood circulation, connected to the brain (cerebral haemodynamics).

Neither has been validated by any meaningful research or recognised authority, and is continuously earning the wrath of influential doctors. Whether it will eventually earn necessary credibility is still doubtful. One can't rule out a destiny for Temple like the Elizabeth Holmes-curated bogus blood-testing startup Theranos.

Also Read | 'Temple is not made for India': Deepinder Goyal responds to criticism in Diwali posts, promises to publish ‘detailed note’

But to understand Temple's potential, you could compare it to de Havilland Comet, pioneer of the commercial jet age, launched in 1952. A resounding success in its early years, later crippled with a metal fatigue-generating structural fallacy, it fast-forwarded the learning curve for Boeing 707 and its many prolific peers. Temple can end up either way.

Examples of semaglutide and tirzepatide - better known as Ozempic and Mounjaro - may be discussed at large. The GLP-1 market reached a moving annual total (MAT) scale of over ₹2,215 cr by mid-2026, with broader industry forecasts estimating the playground to expand significantly. End of one patent regime led to those drugs being made available for 1/10th the original asking price. Perhaps an encore can be expected for the ₹85,000-apiece Temple, as the pioneer inspires wings in empowered followers.

For successful tech products across genres, 'origin' price points invariably reduce dramatically. Else, their stature premium makes it accessible for every aspirational denomination in society. EMI can always be the great leveller, permitting emerging fellows to avail of BMWs and iPhones with rapid felicity.

What needs to be sorted is the core value proposition. Temple is an 'access' technology, not a solution mechanism. It's useful for detecting, in advance, damages that can impair meaningful longevity. Including mental health, which seems to be an underlying epidemic, across strata.

Instead of viewing this as competition, doctors will be well advised to consider advancement as a revenue accelerator. Early detection of potential illnesses, leading to a steady stream of addressable customers. Over time, significantly reducing customer acquisition cost and considerably enhancing customer lifetime value.

Late detection of terminal and chronic non-communicable diseases is a major issue of concern in India, with over 60% of patients across major critical illnesses diagnosed only after reaching advanced or metastatic stages. Diabetes and heart dysfunction add to this diabolical kitty.

Let not the Temple story be reduced to a petty 'doctor v. AI' debate. Instead, let it be seen as an amplifier - today, for a wealthy 'global' customer base; tomorrow, for a much larger 'local' population. Scalable efficacy is never a pioneer's problem, but that of a scalable successor. At this stage, it's necessary for every stakeholder to right-size both Temple's claims and concerns. Whether it will be boom, gloom or doom, we will know soon enough.